Oral rucaparib (600 mg BID) is efficacious in advanced relapsed ovarian carcinoma.
Introduction
The 17-member poly(ADP-ribose) polymerase (PARP) superfamily of nuclear enzymes includes PARP1, PARP2, and PARP3, which are activated by DNA damage and are key mediators in the repair of singlestrand breaks [1] . Inhibition of PARP1, PARP2, and PARP3 results in collapsed DNA replication forks and development of double-strand breaks [2, 3] , which require repair through the BRCA1-and BRCA2-mediated homologous recombination repair pathway [4] [5] [6] . Defects in the homologous recombination repair pathway-for example, a deleterious BRCA1 or BRCA2 (BRCA1/2) mutation-cause homologous recombination deficiency (HRD) and can selectively sensitize tumors to PARP inhibition through synthetic lethality [1, 7, 8] . It is estimated that up to half of high-grade serous ovarian carcinomas may exhibit HRD, with 18% harboring a germline BRCA1/2 mutation and 7% a somatic BRCA1/2 mutation [9] .
Rucaparib (formerly known as CO-338, AG-014447, and PF-01367338) is an oral, small molecule inhibitor of PARP1, PARP2, and PARP3 [10] [11] [12] . In preclinical studies, increased rucaparib-induced cytotoxicity was observed in tumor cell lines with a BRCA1/2 mutation, epigenetically silenced BRCA1, or other DNA repair deficiency [13] . In mouse xenograft models, rucaparib has been shown to slow growth of tumors with a deficiency in BRCA1/2 [13] . In vitro studies have shown that rucaparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes resulting in DNA damage, apoptosis, and cell death [14] . Recently, two international clinical trials-Study 10 (CO-338-010, NCT01482715) [15] and ARIEL2 (CO-338-017, NCT01891344) [16] -demonstrated the antitumor activity of rucaparib in patients with relapsed high-grade serous or endometrioid epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (high-grade ovarian carcinoma [HGOC] ) and a deleterious BRCA1/2 mutation (germline in Study 10; germline or somatic in ARIEL2).
Here, we report integrated analyses of data from Study 10 and ARIEL2 that further characterize the antitumor activity and safety of rucaparib at a starting dose of 600 mg twice daily (BID) in patients with HGOC and a deleterious germline or somatic BRCA1/2 mutation who received at least two prior chemotherapies.
Methods

Constituent study designs
Study 10 and ARIEL2 enrolled patients aged 18 years or older, with a life expectancy of at least 3 months, an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1, and adequate organ function. All patients provided written informed consent. Study 10 is a three-part, open-label, phase I/II study of oral rucaparib given until disease progression or unacceptable toxicity. Part 1 was conducted in patients with a relapsed advanced solid tumor (a known BRCA1/2 mutation was not required) and established rucaparib 600 mg BID as the recommended dose for phase II and phase III evaluation. Part 1 also established that rucaparib could be taken with or without food. Part 2A enrolled patients with platinum-sensitive (disease progression ≥ 6 months after last dose of platinum) relapsed HGOC and a germline BRCA1/2 mutation (detected by local testing) who had received two to four prior therapies. The primary endpoint in Part 2A was confirmed investigator-assessed objective response rate (ORR) per Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST); secondary endpoints included duration of response (DOR), progression-free survival (PFS), and safety. Part 2B of the study enrolled patients with platinum-sensitive, -resistant, or -refractory HGOC with a germline or somatic BRCA1/2 mutation who received three to four prior chemotherapy regimens. The primary endpoint in Part 2B is investigator-assessed ORR. No patients were enrolled in Study 10 Part 2B prior to the enrollment cutoff date of October 1, 2015; thus no data for patients enrolled in Part 2B are included in this analysis. Part 3 enrolled patients with a relapsed solid tumor and a germline or somatic BRCA1/2 mutation (detected by local or central testing) for assessment of the pharmacokinetic and safety profiles of a higher dose tablet of rucaparib.
ARIEL2 is a two-part, phase II, open-label study of oral rucaparib 600 mg BID given until disease progression, unacceptable toxicity, or death in patients with relapsed HGOC. A known BRCA1/2 mutation was not required in ARIEL2; tumor BRCA1/2 status was determined centrally using the Foundation Medicine FoundationFocus™ CDx BRCA assay (Foundation Medicine, Inc., Cambridge, MA, USA) [17] and germline testing of DNA extracted from blood was performed using BROCA-homologous recombination sequencing assay (University of Washington, Seattle, WA, USA) [16, 18] . A somatic BRCA1/2 mutation was defined as a mutation detected in the DNA extracted from tumor tissue but not from blood. For all mutations, biallelic inactivation of BRCA1/2 genes was demonstrated through germline or somatic BRCA1/2 mutation at one allele and loss of heterozygosity of the other allele. Part 1 enrolled patients with platinum-sensitive, relapsed HGOC who had received at least one prior platinum-based regimen and had platinum-sensitive disease. Part 2 is enrolling patients with relapsed HGOC who had received at least three, but not more than four, prior chemotherapies and had a treatment-free interval of N 6 months following first-line chemotherapy. Patients in Part 2 could be platinum-sensitive (disease progression ≥6 months after last platinum), platinum-resistant (disease progression b6 months after last platinum, with best response other than progressive disease [PD]), or platinum-refractory (best response of PD on last platinum with progression-free interval [PFI] b2 months).
In both trials, treatment interruptions and dose reductions were permitted: for patients who received a 600 mg BID starting dose of rucaparib in Study 10 Parts 1 and 2A or ARIEL2 Part 1, dose reduction steps were in 120 mg BID increments (e.g., 600 mg BID to 480 mg BID) down to 240 mg BID. In Study 10 Part 3 and ARIEL2 Part 2, dose reduction steps were in 100 mg BID increments down to 300 mg BID.
In both trials, patients with mild hepatic impairment (defined as alanine/aspartate aminotransferase [ALT/AST] N upper limit of normal [ULN] with total bilirubin ≤ ULN or any ALT/AST level with total bilirubin N1.0-1.5 × ULN) were permitted to enroll. Patients with moderate (defined as ALT/AST level and total bilirubin N 1.5-3 × ULN) or severe (defined as any ALT/AST level and total bilirubin N 3 × ULN) hepatic impairment were excluded.
Integrated analysis datasets
The integrated efficacy population included patients from Study 10 (Part 2A only) and ARIEL2 (Parts 1 and 2) who met the following eligibility criteria: diagnosis of ovarian carcinoma (inclusive of primary peritoneal and fallopian tube carcinoma); received at least one dose of rucaparib 600 mg; received at least two prior chemotherapies, including at least two platinum-based therapies; and had a deleterious BRCA1/2 mutation (germline BRCA1/2 mutation in Study 10; germline or somatic BRCA1/2 mutation in ARIEL2) ( Fig. S1 , Supplementary Data).
To enable a comprehensive evaluation of rucaparib safety in patients with ovarian carcinoma, the integrated safety population included Study 10 (Parts 1, 2A, and 3) and ARIEL2 (Parts 1 and 2) patients with a diagnosis of ovarian carcinoma (inclusive of primary peritoneal and fallopian tube carcinoma) who had taken at least one dose of rucaparib 600 mg. Patients were included in the integrated safety population irrespective of their BRCA1/2 mutation status and number or type of prior therapies.
For both integrated analyses, the study enrollment cutoff date was 
Integrated efficacy analysis outcomes
The primary outcome of interest in the integrated efficacy analysis was investigator-assessed ORR per RECIST, defined as the proportion of patients with a confirmed complete response (CR) or partial response (PR) on subsequent tumor assessment at least 28 days after the first response documentation [19] .
In Study 10 and ARIEL2, tumor assessments included clinical examination and appropriate imaging techniques (preferably computed tomography scans of chest, abdomen, and pelvis, with slice thickness per RECIST); other methods (e.g., magnetic resonance imaging) were utilized if required. In Study 10, assessments were performed at screening, at the end of every 6 weeks (±7 days) of treatment until week 18, and every 9 weeks (±7 days) thereafter; if an initial CR or PR was noted after week 18, confirmatory scans were performed 4 to 6 weeks later. In ARIEL2, assessments were performed at screening and at the end of every 8 weeks (±4 days) of treatment, although for patients who had been on study for at least 18 months, the frequency of tumor assessments could be reduced to every 16 weeks (±2 weeks).
Integrated subgroup analyses for ORR included the number of prior chemotherapies (2 or ≥3), the number of prior platinum-based therapies (2), PFI from the last platinum-based therapy (N12, 6-12, or b-6 months), platinum response status following the last platinumbased therapy (sensitive, resistant, or refractory), age (b65 or ≥ 65 years old), race (white, non-white, or unknown), ECOG PS (0 or 1), and treatment location (US or non-US).
Secondary endpoints included investigator-assessed ORR per Gynecological Cancer InterGroup (GCIG) combined RECIST and cancer antigen 125 (CA-125) criteria, investigator-assessed best response in the sum of target lesions, DOR, and PFS. An independent radiology review of ORR and DOR was also performed. The best response in the sum of target lesions was the percentage change from baseline in the sum of the diameter(s) of all target lesions. DOR was analyzed using Kaplan-Meier methodology; data were censored at the date of the last postbaseline scan for patients who had an ongoing response at the time of the visit cutoff. PFS was also analyzed using Kaplan-Meier methodology, with data censored at the last visit for patients without documented progression or death. Due to the lack of a comparator treatment arm, no statistical testing was performed and no multiplicity adjustment was required. Analyses are presented descriptively.
Integrated safety analysis outcomes
In both trials, safety assessments included adverse event (AE) monitoring and laboratory investigations. Verbatim AE terms were coded using the Medical Dictionary for Drug Regulatory Activities version 18.1 [20] . Severities of the AE and laboratory abnormalities were classified according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03 [9] . Grade 3/4 AEs were managed with dose modification (treatment interruption and/or dose reduction) or treatment discontinuation.
Safety outcomes of interest in the integrated analysis were treatment-emergent AEs of all grades, grade ≥3 treatment-emergent AEs, serious AEs, treatment-related AEs, AEs leading to dose modification (treatment interruption and/or dose reduction), AEs leading to treatment discontinuation, and AEs leading to death.
Results
Integrated efficacy population
The integrated efficacy population included 106 patients from Study 10 Part 2A (n = 42) and ARIEL2 Parts 1 and 2 (n = 64) ( Fig. S1 , Supplementary Data).
At baseline in the integrated efficacy population, median age was 59 (range, 33-84) years, all patients had an ECOG PS of 0 or 1 (61.3% and 38.7%, respectively), and 85.8% of patients had epithelial ovarian, 8.5% had fallopian tube, and 5.7% had primary peritoneal carcinoma ( Table  1 ). All patients had a deleterious BRCA1/2 mutation; 83.0% of patients had a germline BRCA1/2 mutation, and 17.0% had a BRCA1/2 mutation detected in tumor tissue but not in whole blood (i.e., somatic BRCA1/2 mutation). The majority of patients had a BRCA1 mutation (63.2%); the remainder had a BRCA2 mutation (36.8%). Of the nine patients with nonserous ovarian cancer, five had a BRCA1 mutation (2 with mixed, 2 with endometrioid, and 1 with clear cell histology), and four had a BRCA2 mutation (3 with mixed and 1 with endometrioid histology). BRCA1/2 mutation status in tumor was centrally confirmed retrospectively in 96.0% (64/67) of the patients for whom a tumor tissue sample was available for analysis with the companion diagnostic FoundationFocus CDx BRCA assay. All patients received at least two prior lines of chemotherapy (median, 3; range, 2-6), inclusive of platinumbased therapies, 61.3% received three or more prior lines of chemotherapy, and 74.5% exhibited sensitivity to their last platinum-based therapy. The median PFI from the last platinum-based therapy was 8.0 (range, −0.7-116.4) months. 
Integrated efficacy findings
In the integrated efficacy population, the investigator-assessed confirmed ORR per RECIST was 53.8% (95% confidence interval [CI], 43.8-63.5) ( Table 2 ; Fig. 1 ). Best overall investigator-assessed confirmed responses of CR and PR were achieved in 8.5% and 45.3% of patients, respectively; 34.0% of patients had stable disease and 8.5% had PD. The majority of patients (84.9%) had a decrease from baseline in the sum of the diameter of target lesions, with most decreases being ≥ 30% ( Fig. 2A) . For the secondary endpoint of investigator-assessed confirmed response per combined RECIST and GCIG CA-125 criteria, the ORR was 70.8% (95% CI, 61.1-79.2).
Findings from prespecified, exploratory subgroup ORR analyses in the integrated efficacy population are summarized in Fig. 1 . The ORR was similar among patients in several of the subgroups, including patients with a germline or somatic BRCA1/2 mutation and patients with a BRCA1 or BRCA2 mutation. The ORR was higher in patients who had received exactly two prior lines of chemotherapy (inclusive of platinumbased chemotherapy) than in patients who received three or more prior lines of chemotherapy. Patients with a PFI from their last platinum-based therapy N12 months had a higher ORR than those with a PFI of 6 to 12 months or b 6 months. Patients who were sensitive to their most recently administered platinum regimen had a higher ORR than those who were resistant or refractory to their most recent platinum regimen.
In the integrated efficacy population, the median duration of investigator-assessed confirmed response was 9.2 (range, 1.7-19.8; 95% CI, 6.6-11.6) months (Fig. 2B) ; 47.4% of patients with a response had not progressed at the time of the visit cutoff. Investigator-assessed PFS in the integrated efficacy population was 10.0 (range, 0.0-22.1; 95% CI, 7.3-12.5) months ( Fig. S2A, Supplementary Data) ; 47.2% of patients had not progressed at the time of the visit cutoff. The PFS rate at 6 and 12 months was 79.0% and 41.0%, respectively ( Fig. S2A, Supplementary  Data) . Investigator-assessed PFS was 11.1 (95% CI, 7.3-12.8) months in patients who were sensitive to their most recently administered platinum regimen (n = 79), and 7.4 (95% CI, 5.5-not reached) months and 5.3 (95% CI, 1.7-not reached) months in those who were resistant (n = 20) or refractory (n = 7) to their most recent platinum regimen, respectively ( Fig. S2B, Supplementary Data) .
According to the independent radiology review, the confirmed ORR per RECIST in the integrated efficacy population was 41.5% (95% CI, 32.0-51.5); 4.7% of patients achieved a CR and 36.8% achieved a PR. The median DOR according to the independent radiology review was 6.7 (range, 1.7-13.3; 95% CI, 5.5-11.1) months. 
Integrated safety population
The integrated ovarian carcinoma safety population included 377 patients from Study 10 Parts 1, 2A, and 3 (n = 62), and ARIEL2 Parts 1 and 2 (n = 315) ( Fig. S1, Supplementary Data) . The median duration of rucaparib treatment in the integrated safety population was 5.5 (range, 0.1-28.0) months.
At baseline in the integrated safety population, median age was 62 (range, 31-86) years. All patients had an ECOG PS of 0 or 1 (61.8% and 38.2%, respectively); 80.9% of patients had epithelial ovarian carcinoma (Table 1) . Approximately one-third of patients (37.9%) had a deleterious BRCA1/2 mutation (germline or somatic). All patients had received at least one prior line of chemotherapy; 43.8% had received three or more prior lines of chemotherapy (inclusive of platinum-based therapies), and 27.1% had received three or more platinum-based therapies.
Integrated safety findings
All patients in the integrated safety population had at least one treatment-emergent AE, and 60.7% had a grade ≥3 treatment-emergent AE. The most frequently reported treatment-emergent AEs were nausea (76.9%), asthenia/fatigue (76.7%), vomiting (46.2%), anemia/hemoglobin decreased (43.8%), and ALT/AST increased (41.4%) ( Table 3) . Median time to onset of anemia (preferred term only) was approximately 54 days. Common grade ≥ 3 treatment-emergent AEs included anemia/hemoglobin decreased (24.9%), asthenia/fatigue (10.9%), and ALT/ AST increased (10.9%). Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) were reported as an AE in one patient each after 57 and 539 days of rucaparib treatment, respectively; both patients had received at least 12 cycles of prior platinum-based therapy, and neither patient had a BRCA1/2 mutation. Immediately following the MDS and AML diagnosis, rucaparib treatment was discontinued.
The most frequently observed lab abnormalities were increase in creatinine (any worsening in grade, 92.0%; shift to grade 3/4, 1.3%), increase in ALT (any worsening in grade, 74.0%; shift to grade 3/4, 12.5%), increase in AST (any worsening in grade, 73.2%; shift to grade 3/4, 4.5%), and decrease in hemoglobin (any worsening in grade, 66.6%; shift to grade 3/4, 23.3%) ( Table 3 ). Creatinine increases were observed within the first few weeks of rucaparib treatment and then stabilized with continued rucaparib treatment (Fig. 3A) .
Elevations in ALT/AST were also observed within the first few weeks of rucaparib treatment (Fig. 3B) . These elevations were mostly asymptomatic, reversible, and were rarely associated with increases in bilirubin (Fig. 3C) ; the elevations generally normalized over time with continued treatment and only resulted in treatment discontinuation in one patient (0.3%). At study entry, 32 patients had mild hepatic impairment, and 345 patients had no hepatic impairment. There was no difference in the incidence of all-grade treatment-emergent AEs between patients with or without mild hepatic impairment (100% in each group). The incidence of grade 3 or higher treatment-emergent AEs was reported in 59.4% and 60.9% of patients with or without mild hepatic impairment, respectively.
Treatment-emergent AEs led to treatment interruption in 58.6% of patients and dose reduction in 45.9% of patients (Table 3) . AEs most frequently leading to dose modification (dose reduction or treatment interruption) included anemia/hemoglobin decreased (21.5%), asthenia/ fatigue (20.7%), nausea (18.0%), vomiting (11.9%), ALT/AST increased (10.3%), and thrombocytopenia/platelets decreased (9.8%). Treatmentemergent AEs led to treatment discontinuation in 9.8% of patients (excluding those who discontinued because of disease progression) ( Table 3) . Treatment-emergent AEs leading to treatment discontinuation in five or more patients included asthenia/fatigue (2.4%) and nausea (1.3%).
An AE with an outcome of death occurred in 2.4% of patients (9 deaths). Of those deaths, 8 were associated with malignant neoplasm progression. The ninth patient died from sepsis and clinical progression, which was assessed by the investigator to be unrelated to rucaparib treatment.
Discussion
Results from this integrated analysis demonstrate that oral rucaparib (600 mg BID) has antitumor activity in patients with HGOC and a deleterious germline or somatic BRCA1/2 mutation who have received two or more prior chemotherapies. More than half (53.8%) of patients with HGOC achieved a CR (8.5%) or PR (45.3%). Responses to rucaparib were durable, with a median DOR of 9.2 months. Based on these results, single-agent rucaparib received accelerated approval from the United States Food and Drug Administration in December 2016 for treatment of women with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies.
Results of the integrated efficacy analysis also demonstrated antitumor activity in subgroups within the efficacy population. Notably, the ORR was higher in patients who had received only two prior chemotherapies (68.3%) than in those who received three or more prior chemotherapies (44.6%). The ORR was also higher in platinum-sensitive patients (65.8%) than in platinum-resistant (25.0%) or platinum- Table 3 Safety summary: all patients with ovarian carcinoma who received ≥1 dose of rucaparib 600 mg BID.
Summary of AEs
Integrated ovarian carcinoma safety population (n = 377) a n (%) AE leading to dose modification (dose reduction or treatment interruption) refractory (0.0%) patients; however, patients in all three subgroups appeared to derive some measure of clinical benefit as demonstrated by the median PFS in each subgroup (11.1, 7.4, and 5.3 months, respectively). Additionally, this analysis showed that the ORR was similar between patients with a germline or somatic BRCA1/2 mutation and between patients with a BRCA1 or BRCA2 mutation.
Other PARP inhibitors, including olaparib, veliparib, and niraparib, have also been investigated in ovarian carcinoma in the treatment setting. In Study 42, olaparib had an ORR of 33.6%, a median DOR of 7.9 months, and median PFS of 6.7 months in patients with advanced ovarian carcinoma and a germline BRCA1/2 mutation who had received at least three prior chemotherapies [21] . In a phase II trial, treatment with veliparib led to an ORR of 26.0% and a median PFS of 8.2 months in patients with recurrent ovarian carcinoma and a germline BRCA1/2 mutation who had received up to three prior chemotherapies [22] . Niraparib is currently being evaluated in the treatment setting for patients with ovarian cancer who have received three to four prior chemotherapies (QUADRA; NCT02354586). At this time, we are not aware of any head-to-head trials of PARP inhibitors in the setting of HGOC; thus, direct comparisons cannot be made between agents in this class. If indirect comparisons were to be made, they would likely be confounded by differences in patient populations, tumor histologies and/ or subtype, trial design, and study execution. Nevertheless, a common observation within clinical trials that have investigated PARP inhibitors is that patients with platinum-sensitive disease are more likely to respond to PARP inhibitors than patients with platinum-resistant or platinum-refractory disease [23, 24] . In the United States, olaparib is approved as a monotherapy in the treatment setting for patients with HGOC and a germline BRCA1/2 mutation who have received three or more prior chemotherapies. In the European Union, olaparib is approved as monotherapy for the maintenance treatment of patients with platinum-sensitive, relapsed, BRCA-mutated (germline and/or somatic), high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in remission (CR or PR) to platinum-based therapy. Niraparib and olaparib are approved in the United States as monotherapy for maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.
The integrated safety analysis in patients with ovarian carcinoma demonstrated that rucaparib has a manageable safety profile. In the setting of these two trials, treatment-emergent AEs and lab abnormalities were managed with treatment interruption, treatment modification, and/or supportive care such as antiemetic medications for nausea or vomiting (e.g., 5-HT antagonist and a corticosteroid with or without a NK1 antagonist or palonosetron with dexamethasone) or red blood cell transfusions for anemia. Treatment discontinuations due to treatment-emergent AEs not related to disease progression were infrequent (9.8%). Furthermore, gastrointestinal side effects, asthenia/fatigue, and myelosuppression are consistent with toxicities already observed with the PARP inhibitor class of agents [21, 22, 24, 25] .
Creatinine increases observed with rucaparib were predominantly grade 1 or 2 and usually occurred within the first few weeks of rucaparib treatment and then stabilized. In the setting of these two trials, mild to moderate elevations in serum creatinine did not require dose modification. In vitro studies have shown that rucaparib potently inhibits MATE1 and MATE2-K and moderately inhibits OCT-1 [26] , renal transporters that play a role in the secretion of creatinine into the proximal tubule and subsequent apical efflux into urine. Olaparib has been shown to inhibit MATE1, MATE2-K, and OCT2 in vitro [27] ; veliparib also inhibits MATE1 and MATE2-K in vitro [28] . Increases in creatinine have also been observed following the use of olaparib in the setting of advanced ovarian cancer [29] . Thus, increases in blood creatinine observed following rucaparib treatment may be a PARP inhibitor class effect.
Observed ALT/AST elevations were transient and normalized over time with continued rucaparib treatment. Although no differences were observed in the rate of AEs in patients with or without mild hepatic impairment, a clinical pharmacokinetic study will be completed to determine the most appropriate starting dose for rucaparib in patients with moderate hepatic impairment.
A limitation of this integrated analysis is that these data were generated from two open-label, single-arm, nonrandomized phase II trials with unique study designs and overlapping patient populations. Furthermore, randomized data are not yet available for rucaparib in the treatment setting; however, a phase III trial is underway to further evaluate rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian carcinoma with a BRCA1/2 mutation in the treatment setting (ARIEL4; NCT02855944). Rucaparib is also being compared with placebo in patients with ovarian carcinoma in a phase III trial in the maintenance treatment setting (ARIEL3; NCT01968213). Both phase III trials will explore the use of biomarkers, including BRCA1/2 mutations, for predicting response to rucaparib treatment in patients with HGOC.
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